Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TmBU vs mBUCY Conditioning Regimen Before Allo-HSCT in High-risk or Relapsed/Refractory Acute Leukemia
NCT06816134Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of busulfan + melphalan + thiotepa in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Cumulative incidence of relapse at 2 years. Started Jan 2025; status: recruiting.
02
Drugs
busulfan + melphalan + thiotepa
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06816134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816134.